Alberto Vitari

Alberto Vitari, Ph.D. has extensive and diverse experience driving and delivering target identification and validation programs. He is proficient in cancer genomics, functional genetics, and leveraging bioinformatics tools to identify novel targets that serve as a basis for drug development. ​Prior to Rubedo Life Sciences, he was Group Leader, Molecular and Cellular Biology at Verily (formerly Google Life Sciences), and​ Group Leader at Novartis Institutes for BioMedical Research. At Novartis, Alberto was responsible for the identification of novel oncology molecular targets. He has expertise in cell signaling, cancer genetics, mechanism of action elucidation, and data integration to guide patient selection. ​He served as a postdoctoral scientist at Genentech and at Pharmacy Corporation in Italy. His scientific record includes top-tier publications in Cell, Science, and Nature, including a seminal work on proto-oncogenic factors (Vitari et al., Nature, 2011).